<DOC>
	<DOCNO>NCT02918188</DOCNO>
	<brief_summary>This study suggest hydrogen potential effective safe therapeutic agent cGVHD .</brief_summary>
	<brief_title>Therapeutic Effects Hydrogen Steroid-refractory/or Steroid-dependent cGVHD</brief_title>
	<detailed_description>The investigator evaluate clinical response rate , time treatment Failure ( TTF ) , overall survival ( OS ) , toxicity cGVHD patient .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Written inform consent Male pregnant female patient &lt; 65 year old Diagnosis cGVHD steroid refractory ( response Prednisone â‰¥1mg/kg ) steroiddependent cGVHD ( initial response follow cGVHD flare upon steroid taper ) Patient intolerant steroid therapy Patients stable disease , well control current treatment Pregnancy HIV positive Severe liver renal impairment : serum creatinine &gt; 2.5 mg/dl ; serum bilirubin &gt; 2.5 mg/dl ( without evidence hepatic cGVHD ) Uncontrolled malignancy include persistence underlying malignancy Allogeneic Transplantation relapse hematopoietic malignancy Any investigational agent administer within last four week Cardiac insufficiency ( &gt; grade II , New York Heart Association classification ) Inability comply medical therapy followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>